Predicting risk for new-onset type 2 diabetes in Chinese people with coronary heart disease and impaired glucose tolerance
Prif Awduron: | Xu, S, Scott, C, Coleman, RL, Tuomilehto, J, Holman, RR |
---|---|
Fformat: | Conference item |
Iaith: | English |
Cyhoeddwyd: |
Springer Nature
2019
|
Eitemau Tebyg
-
Predicting the risk of developing type 2 diabetes in Chinese people who have coronary heart disease and impaired glucose tolerance
gan: Xu, S, et al.
Cyhoeddwyd: (2021) -
Predicting heart failure events in patients with coronary heart disease and impaired glucose tolerance: insights from the Acarbose Cardiovascular Evaluation (ACE) trial
gan: Wamil, M, et al.
Cyhoeddwyd: (2020) -
Health utilities in Chinese patients with coronary heart disease and impaired glucose tolerance (ACE): a longitudinal analysis of a randomized, double-blind, placebo-controlled trial
gan: Leal, J, et al.
Cyhoeddwyd: (2022) -
Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial
gan: Holman, R, et al.
Cyhoeddwyd: (2017) -
Effect of valsartan on kidney outcomes in people with impaired glucose tolerance.
gan: Currie, G, et al.
Cyhoeddwyd: (2017)